A new Lyme disease vaccine is about to enter its final phase of human trialling. If all goes well it could be available by 2025, making it the first vaccine for Lyme disease to reach the market in...
PureSoftware, with its business-driven approach, has been helping pharma and medtechs from doing digital to being digital.
With the incredible popularity of “How to Change Your Mind,” Michael Pollan sells people on psychedelic treatments that are not yet available
Neuroscientific Biopharmaceuticals (ASX:NSB) aim for clinical trials for EmtinB, will become a key treatment for MS and Alzheimer’s disease.
Here, EPR examines the trends that look set to shape clinical research in 2022, with comment from Aman Khera of Worldwide Clinical Trials.
The road to psychedelic legalization has many paths. These 3 clinical trials have the best chances to legalize psychedelics for therapy